keyword
MENU ▼
Read by QxMD icon Read
search

hiv dlbcl

keyword
https://www.readbyqxmd.com/read/29187222/unusual-presentation-of-plasmablastic-lymphoma-involving-ovarian-mature-cystic-teratoma-a-case-report
#1
Ita Hadžisejdić, Emina Babarović, Luka Vranić, Antica Duletić Načinović, Ksenija Lučin, Maja Krašević, Nives Jonjić
BACKGROUND: Plasmablastic lymphoma (PBL) is relatively new clinical entity described as a distinct subtype of diffuse large B-cell lymphoma (DLBCL). It is characterized by its aggressive nature and proliferation of large neoplastic cells resembling immunoblasts including cells with more obvious plasmacytic differentiation. In this case report, we describe an unexpected finding of PBL associated with a mature cystic teratoma of the ovary in a young immune competent woman. CASE PRESENTATION: A 19-year old woman was admitted to the hospital with generalized lymphadenopathy, a pelvic tumor mass measuring 35 × 30 cm and a 4 cm lump in her right breast...
November 29, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/29066707/fast-growing-subcutaneous-tumors-with-lower-extremity-edema-and-rib-lesions-a-case-of-non-hodgkin-s-lymphoma-in-an-hiv-1-infected-patient
#2
Man Lai, Xiuqun Zhang, Qunhui Li, Caiping Guo, Yulin Zhang
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) accounts for the large majority of AIDS-related non-Hodgkin's lymphoma (NHL). DLBCL usually arises in lymph nodes, presenting as a painless rapid swelling mass in the neck, armpit, or groin. CASE REPORT Here, we report a case of DLBCL that needed only 3 months to develop a tumor 20×15 cm in diameter in the right groin and even caused scrotum swelling and lower-extremity edema. Furthermore, this case of DLBCL had developed other 3 subcutaneous tumors in the chest wall and their diameters were 16×9 cm, 7×7 cm, and 3×3 cm...
October 25, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29019447/survival-of-patients-with-cd20-negative-variants-of-large-b-cell-lymphoma-an-analysis-of-the-national-cancer-data-base
#3
Lindor Qunaj, Jorge J Castillo, Adam J Olszewski
Using records from the National Cancer Data Base, we studied overall survival of CD20-negative variants of diffuse large B-cell lymphoma (DLBCL): primary effusion (PEL, N = 228), plasmablastic (PBL, N = 481), ALK-positive large B-cell (ALK + LBLC, N = 15), and human herpesvirus-8-positive DLBCL (HHV8 + DLBCL, N = 77). Three-year survival was 27% for PEL, 40% for PBL, 34% for ALK + LBCL, and 63% for HHV8 + DLBCL. Compared with unspecified DLBCL, and adjusting for clinical characteristics (including the HIV status), survival was significantly worse for PEL (hazard ratio [HR], 1...
October 11, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28982264/de-novo-unclassifiable-cd20-negative-diffuse-large-b-cell-lymphoma-a-diagnostic-and-therapeutic-challenge
#4
Badr AbdullGaffar, Rania M Seliem
CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-documented variants include plasmablastic lymphomas, primary effusion lymphomas, anaplastic kinase-positive large B-cell lymphomas, and large B-cell lymphomas arising in human herpesvirus 8 (HHV8)-associated multicentric Castleman disease. They impose diagnostic challenges for pathologists and therapeutic confrontations for clinicians. CD20 loss in B-cell lymphomas is a well-known phenomenon after rituximab therapy...
October 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28926410/outcomes-for-hiv-associated-diffuse-large-b-cell-lymphoma-in-the-modern-combined-antiretroviral-therapy-era
#5
Caroline Besson, Remi Lancar, Sophie Prevot, Michele Algarte-Genin, Pierre Delobel, Fabrice Bonnet, Marie-Caroline Meyohas, Marialuisa Partisani, Lucie Oberic, Jean Gabarre, Cécile Goujard, François Boue, Paul Coppo, Regis Costello, Houria Hendel-Chavez, Nawel Mekerri, Gabriella Dos Santos, Christian Recher, Richard Delarue, Rene-Olivier Casasnovas, Yassine Taoufik, Nicolas Mounier, Dominique Costagliola
OBJECTIVE: Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival among patients with HIV-associated diffuse large B-cell lymphoma (DLBCL), the most frequent NHL subtype, has improved markedly in recent years. We aimed to analyze characteristics and outcomes of DLBCL in HIV-infected patients in the era of modern combined antiretroviral therapy (cART). DESIGN: PLWHIV with lymphoma were prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015...
November 28, 2017: AIDS
https://www.readbyqxmd.com/read/28800008/epstein-barr-virus-infection-can-be-a-secondary-event-in-b-cell-lymphomas-a-review-of-338-cases-and-a-novel-finding-of-zonal-eber-tumor-cells-showing-features-of-progression-from-underlying-ebv-negative-lymphoma
#6
Ira J Miller
Cases of B-cell lymphoma over an 8-year interval with diagnosis of EBER positivity were retrieved from archives and reviewed for classification and pattern of Epstein Barr Virus (EBV) expression. Of 46 cases that were EBV early RNA (EBER)+ by in situ hybridization staining, 7 had nonuniform staining among the neoplastic cells. Four of those cases showed a uniform admixture of EBER+ and EBER- tumor cells, compatible with the prevailing theory of episomal EBV loss with cell replication. Three cases of lymphomas showed a partial and zonal pattern and other features suggest that EBV infection occurred after the lymphoma was already established...
August 9, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28717763/burkitt-s-lymphoma-and-b-cell-lymphoma-unclassifiable-with-features-intermediate-between-diffuse-large-b-cell-lymphoma-and-burkitt-s-lymphoma-in-patients-with-hiv-outcomes-in-a-south-african-public-hospital
#7
Gerhard Sissolak, Matthew Seftel, Thomas S Uldrick, Tonya M Esterhuizen, Nooroudien Mohamed, Danie Kotze
PURPOSE: Burkitt's lymphoma (BL) is a common HIV-associated lymphoma in South Africa. B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma (BL/DLBCL) also occurs in HIV infection. Outcomes of HIV-infected patients with BL or BL/DLBCL in a resource-constrained setting are not defined. METHODS: We performed a retrospective study of HIV-positive patients with BL or BL/DLBCL treated from 2004 to 2012 with curative intent at a publically funded academic medical center in South Africa...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28702826/head-and-neck-diffuse-large-b-cell-lymphomas-hn-dlbcl-in-human-immunodeficiency-virus-hiv-positive-patients-long-term-results-in-the-highly-active-antiretroviral-therapy-haart-era
#8
Francesca De Felice, Andrea Di Mino, Lavinia Grapulin, Maria Lusia Mistrulli, Daniela Musio, Vincenzo Tombolini
To report long-term outcomes and toxicity rates after chemotherapy (CHT) followed by radiotherapy (RT) in the highly active antiretroviral therapy (HAART) era in human immunodeficiency virus (HIV) positive patients with head and neck diffuse large B cell lymphomas (HN-DLBCL). Clinical data concerning consecutive HIV patients treated for DLBCL located in head and neck region with CHT and RT were retrospectively reviewed. Systemic treatment consisted of combination CHT agents given with concomitant HAART and regimen was left to oncologists' discretion...
July 12, 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/28610450/novel-tumor-markers-provide-improved-prediction-of-survival-after-diagnosis-of-human-immunodeficiency-virus-hiv-related-diffuse-large-b-cell-lymphoma
#9
Chun Chao, Michael J Silverberg, Lie-Hong Chen, Lanfang Xu, Otoniel Martínez-Maza, Donald I Abrams, Hongbin D Zha, Reina Haque, Jonathan Said
Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohistochemistry staining was used to analyze the expression of 26 tumor markers. Clinical data were collected from medical records. Logistic regression and bootstrapping were used to select and assess stability of the prognostic model, respectively...
February 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28559819/two-year-complete-remission-of-diffuse-large-b-cell-lymphoma-in-an-immunological-nonresponder-hiv-infected-patient-case-report
#10
Miodrag Vrbic, Ivan Petkovic, Svetislav Vrbic, Maja Jovanovic, Aleksandar Rankovic, Lidija Popovic-Dragonjic, Marina Djordjevic-Spasic
INTRODUCTION: HIV-infected patients are affected significantly more frequently by all types of lymphoma, with diffuse large B-cell lymphoma (DLBCL) as the most prevalent histological type. Since the introduction of combination antiretroviral therapy (cART) morbidity and mortality of DLBCL has been markedly reduced, which is primarily interpreted as a result of the drug-mediated immune reconstitution. CASE REPORT: We present a previously healthy, 44-year-old HIV-infected man with DLBCL of the oral cavity, treated with immunochemotherapy and cART...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28507339/efficacy-and-tolerability-of-chemotherapy-in-chinese-patients-with-aids-related-burkitt-lymphoma-and-diffuse-large-b-cell-lymphoma-an-observational-study
#11
Jiang Xiao, Shuxu Du, Guorui Dai, Guiju Gao, Di Yang, Hongxin Zhao
We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33...
May 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28279031/-clinicpathological-features-and-survival-of-patients-with-aids-related-non-hodgkin-s-lymphoma
#12
K Y Sun, X E Gui, D Deng, Y Xiong, L P Deng, S C Gao, Y X Zhang
Objective: To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (ARL) . Methods: The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability. Results: The mean age of patients with ARL was 43 (11-67) years...
February 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/28219694/lenalidomide-maintenance-in-patients-with-relapsed-diffuse-large-b-cell-lymphoma-who-are-not-eligible-for-autologous-stem-cell-transplantation-an-open-label-single-arm-multicentre-phase-2-trial
#13
Andrés J M Ferreri, Marianna Sassone, Francesco Zaja, Alessandro Re, Michele Spina, Alice Di Rocco, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Chiara Rusconi, Renato Zambello, Suzana Couto, Yan Ren, Annalisa Arcari, Giovanni Bertoldero, Alessandro Nonis, Lydia Scarfò, Teresa Calimeri, Caterina Cecchetti, Marianna Chiozzotto, Silvia Govi, Maurilio Ponzoni
BACKGROUND: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having relapse after ASCT have a low likelihood of cure. Single-drug maintenance after salvage therapy might be an attractive strategy to prolong survival in these patients. Lenalidomide is a suitable candidate for long-lasting maintenance as it is an oral drug, active against DLBCL that can be taken for years with an acceptable toxicity profile. We designed a study to investigate safety and efficacy of lenalidomide maintenance in patients with chemosensitive relapse of DLBCL not eligible for ASCT or having relapse after ASCT...
February 16, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28192480/mtor-activity-in-aids-related-diffuse-large-b-cell-lymphoma
#14
Sara H Browne, Julio A Diaz-Perez, Michael Preziosi, Charles C King, George A Jones, Sonia Jain, Xiaoying Sun, Erin G Reid, Scott VandenBerg, Huan-You Wang
BACKGROUND: Patients infected with HIV have a significantly increased risk of developing non-Hodgkin lymphomas despite the widespread use of HAART. To investigate mTOR pathway activity in acquired immunodeficiency syndrome (AIDS) related diffuse large B-cell lymphoma AR-DLBCL, we used immunohistochemistry to examine the presence of the phosphorylated 70 ribosomal S6 protein-kinase (p70S6K), an extensively studied effector of mTOR Complex 1 (mTORC1) and the phosphorylated phosphatase and tensin homolog (pPTEN), a negative regulator of mTORC1 pathway...
2017: PloS One
https://www.readbyqxmd.com/read/28127387/clinical-and-prognostic-analysis-of-78-patients-with-human-immuno-deficiency-virus-associated-non-hodgkin-s-lymphoma-in-chinese-population
#15
Yang Shen, Renfang Zhang, Li Liu, Yinzhong Shen, Wei Song, Tangkai Qi, Yang Tang, Zhenyan Wang, Liqian Guan, Hongzhou Lu
BACKGROUND: Human Immuno-deficiency Virus (HIV) associated non-Hodgkin's lymphoma (NHL) was a special group of disease, which manifests distinct clinical features and prognosis as compared with NHLs in patients without HIV. We performed this study to describe the clinical features of the disease and investigated the potential prognostic factors. METHODS: HIV-infected patients who were newly diagnosed with NHL were enrolled in this study. The selection of anti-lymphoma treatment regimen was mainly dependent on the pathological subtypes of NHLs...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28094666/stage-iv-advanced-diffuse-large-b-cell-lymphoma-in-human-immunodeficiency-virus-infection-with-achieving-cure-by-using-highly-active-antiretroviral-therapy-alone-a-case-report
#16
Do Hyoung Lim, Ji-Young Rhee, Keon Woo Park
After the introduction of highly active antiretroviral therapy (HAART), there has been a decrease in the incidence of lymphoma among the HIV-infected population and also significantly improved survival rates. We describe a remarkable case of an HIV-infected patient with advanced stage IV diffuse large B-cell lymphoma (DLBCL), completely regressed with the use of HAART alone. He remained disease-free for 6 years and he achieved cure without chemotherapy. Although several cases of low-grade lymphoma with complete regression were reported, we could not find any case of stage IV high-grade malignant lymphoma with HAART alone in complete remission for over 5 years from our review of the literature...
January 1, 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28031174/clinical-characteristics-and-prognostic-factors-of-plasmablastic-lymphoma-patients-analysis-of-135-patients-from-the-lysa-group
#17
E Tchernonog, P Faurie, P Coppo, H Monjanel, A Bonnet, M Algarte Génin, M Mercier, J Dupuis, F Bijou, C Herbaux, A Delmer, B Fabiani, C Besson, S Le Gouill, E Gyan, C Laurent, H Ghesquieres, G Cartron
Background: Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse large B-cells lymphoma by the World Health Organization (WHO) classification. Since the original description, others cases have been reported. However, these are largely derived from case reports or small series limiting any definitive conclusions on clinical characteristics and outcome. Patients and methods: The clinical, biological, pathological features and outcome of a cohort including 135 patients with PBL, from LYSA centers in France and Belgium, were reported and analyzed...
April 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27957358/bortezomib-ifosfamide-carboplatin-and-etoposide-in-a-patient-with-hiv-negative-relapsed-plasmablastic-lymphoma
#18
Mehmet Akce, Elaine Chang, Mohammad Haeri, Mike Perez, Christie J Finch, Mark M Udden, Martha P Mims
Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B cell lymphoma (DLBCL), often associated with HIV infection. We present a case of a 53-year-old HIV-negative man with untreated hepatitis C viral infection who presented with abdominal pain and lymphadenopathy. Lymph node and bone marrow biopsies were consistent with plasmablastic lymphoma. He had partial response (PR) to 6 cycles of EPOCH but disease progressed seven weeks later. Repeat biopsy was consistent with plasmablastic lymphoma. Three cycles of bortezomib, ifosfamide, carboplatin, and etoposide (B-ICE) chemotherapy resulted in a partial response (PR)...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27782313/cytotoxic-epstein-barr-virus-positive-large-b-cell-lymphoma-a-regulatory-b-cell-derived-neoplasia
#19
Valentina Tabanelli, Vanessa Santiago-Pacheco, Mario Corbellino, Angelica Calleri, Claudio Agostinelli, Carlo Parravicini, Stefano A Pileri
AIMS: A new subtype of granzyme B (GrB)-producing regulatory B cells (Bregs ) has been described recently; these peculiar cytotoxic B cells are increased significantly in interleukin (IL)-21-rich settings, and in particular during HIV and Epstein-Barr virus (EBV) infection. Our aim is to report a unique case of an EBV-positive diffuse large B cell lymphoma (DLBCL) with cytotoxic features arisen in an HIV(+) patient, and to understand if this lesion may represent a proliferation of neoplastic cytotoxic Bregs ...
March 2017: Histopathology
https://www.readbyqxmd.com/read/27756777/hiv-infection-and-survival-of-lymphoma-patients-in-the-era-of-highly-active-antiretroviral-therapy
#20
Xuesong Han, Ahmedin Jemal, Erin Hulland, Edgar P Simard, Loretta Nastoupil, Elizabeth Ward, Christopher R Flowers
Background: Highly active antiretroviral therapy (HAART) has extended the life expectancy of patients with HIV/AIDS to approach that of the general population. However, it remains unclear whether HIV infection affects the survival of patients with lymphoma in the HAART era.Methods: Patients diagnosed with Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, peripheral T-cell lymphoma (PTCL), or follicular lymphoma during 2004-2011 were identified from the National Cancer Database. Survival analyses were conducted, where each HIV-infected patient was propensity score matched to a HIV-uninfected patient on the basis of demographic factors, clinical features, and treatment characteristics...
October 18, 2016: Cancer Epidemiology, Biomarkers & Prevention
keyword
keyword
119373
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"